Back to top
more

Ginkgo Bioworks (DNA)

(Delayed Data from NYSE)

$0.29 USD

0.29
61,074,895

-0.03 (-10.02%)

Updated Jul 12, 2024 04:00 PM ET

After-Market: $0.29 0.00 (0.66%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

by Zacks Equity Research

The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $0.32, representing a -1.51% change from its previous close.

After Plunging -40.22% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA)

by Zacks Equity Research

Ginkgo Bioworks (DNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ginkgo Bioworks (DNA) delivered earnings and revenue surprises of 0% and 16.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 0% and 20.81%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Ginkgo (DNA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Ginkgo's (DNA) fourth-quarter earnings call, investor focus is likely to be on the sales performance of its two business units, Biosecurity and Cell Engineering.

Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -13.27% and 0.15%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Ginkgo (DNA) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Ginkgo's (DNA) third-quarter earnings call, investor focus is likely to be on the sales performance of its two business units ¿¿¿ Biosecurity and Cell Engineering.

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 0% and 14.43%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 11.11% and 30.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Anika Therapeutics (ANIK) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Anika (ANIK) delivered earnings and revenue surprises of -97.22% and 2.05%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Ligand Pharmaceuticals (LGND) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Ligand (LGND) delivered earnings and revenue surprises of 121.36% and 12.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 86.67% and 16.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of -60% and 22.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Poseida Therapeutics, Inc. (PSTX) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 235.29% and 5,715.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) delivered earnings and revenue surprises of 14.29% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

2seventy bio, Inc. (TSVT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of -1.15% and 25.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ginkgo (DNA) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Ginkgo's (DNA) third-quarter earnings call, investor focus is likely to be on the company's progress with its collaboration deals and the performance of its business units.

IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 8.97% and 15.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ginkgo Bioworks Holdings, Inc. (DNA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) closed at $2.74 in the latest trading session, marking a +0.37% move from the prior day.

Ginkgo Bioworks Holdings, Inc. (DNA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $2.78, marking a +0.72% move from the previous day.

Ginkgo Bioworks Holdings, Inc. (DNA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) closed at $2.63 in the latest trading session, marking a +1.54% move from the prior day.

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $2.84, moving -0.35% from the previous trading session.

Ginkgo Bioworks Holdings, Inc. (DNA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $3.14, moving +0.64% from the previous trading session.

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Moves -0.32%: What You Should Know

by Zacks Equity Research

In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $3.12, marking a -0.32% move from the previous day.

Ginkgo Bioworks Holdings, Inc. (DNA) Could Find Support Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.